T-cell engagers (TCEs) drive synthetic antitumor immunity by bypassing endogenous T-cell priming and directly inducing tumor cell killing. In prostate cancer, targeting prostate-restricted antigens such as STEAP2, combined with CD8-guided TCE formats that favor cytotoxic T-cell engagement, offers a strategy to reduce cytokine release while maintaining antitumor activity. Researchers from Astrazeneca plc reported the design and preclinical characterization of AZD-8359, a bispecific TCE featuring dual anti-STEAP2 binding domains, an anti-TCR stimulation domain, and an additional CD8-guiding arm.